抗体-オリゴヌクレオチド複合体（AOC）の世界市場分析 : 2031年までの予測

本レポートは、2020年から2024年までの抗体-オリゴヌクレオチド複合体（AOC）の収益、市場シェア、主要企業の業界ランキングに焦点を当てています。世界の抗体オリゴヌクレオチド複合体（AOC）市場における主要なステークホルダーを特定し、最近の動向とセグメント別収益に基づいて、それぞれの競争環境と市場ポジショニングを分析しています。本レポートは、ステークホルダーが競争環境を理解し、より多くの洞察を得て、事業と市場戦略をより適切に位置付けるのに役立ちます。

The global Antibody-oligonucleotide Conjugates (AOCs) market is projected to grow from US$ 3.12 million in 2026 to US$ 291.41 million by 2031, at a Compound Annual Growth Rate (CAGR) of 147.78% during the forecast period (2026-2031).

世界の抗体-オリゴヌクレオチド複合体（AOC）市場は、予測期間（2026～2031年）中に147.78%の複合年間成長率（CAGR）で、2026年の312万米ドルから2031年には2億9,141万米ドルに成長すると予測されています。

The US & Canada market for Antibody-oligonucleotide Conjugates (AOCs) is estimated to increase from $ 2.04 million in 2026 to reach $ 165.03 million by 2031, at a CAGR of 140.81% during the forecast period of 2026 through 2031.

The Europe market for Antibody-oligonucleotide Conjugates (AOCs) is estimated to increase from $ 1.08 million in 2026 to reach $ 96.95 million by 2031, at a CAGR of 145.73% during the forecast period of 2026 through 2031.

The global key companies of Antibody-oligonucleotide Conjugates (AOCs) include Avidity Biosciences, Dyne Therapeutics, Tallac Therapeutics, Gennao Bio, ChainGen Bio and Denali Therapeutics, etc. As innovations continue to emerge in the field of AOCs, competition is also gradually intensifying. Major companies continue to launch new drug candidates, especially in the fields of cancer and neurodegenerative diseases, and the competition for market share will become more intense.

Report Includes

This report presents an overview of global market for Antibody-oligonucleotide Conjugates (AOCs) market size. Analyses of the global market trends, with historic market revenue data for 2020 – 2024, estimates for 2024, and projections of CAGR through 2031.

This report researches the key producers of Antibody-oligonucleotide Conjugates (AOCs), also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Antibody-oligonucleotide Conjugates (AOCs), and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Antibody-oligonucleotide Conjugates (AOCs) revenue, market share and industry ranking of main companies, data from 2020 to 2024. Identification of the major stakeholders in the global Antibody-oligonucleotide Conjugates (AOCs) market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2020 to 2031. Evaluation and forecast the market size for Antibody-oligonucleotide Conjugates (AOCs) revenue, projected growth trends, production technology, application and end-user industry.

Descriptive company profiles of the major global players, including Avidity Biosciences, Dyne Therapeutics, Tallac Therapeutics, Gennao Bio, ChainGen Bio and Denali Therapeutics, etc.

Market Segmentation

By Company

•             Avidity Biosciences
•             Dyne Therapeutics
•             Tallac Therapeutics
•             Denali Therapeutics
•             Gennao Bio
•             ChainGen Bio

Segment by Type

•             Site-specific Conjugation

Random Conjugation

•             Segment by Application
•             Rare and Genetic Diseases
•             Cancer Treatment
•             Central Nervous System Disorders

By Region

North America

•             United States
•             Canada

Asia-Pacific

•             China
•             Japan
•             South Korea
•             Southeast Asia
•             India
•             Australia
•             Rest of Asia

Europe

•             Germany
•             France
•             U.K.
•             Italy
•             Russia
•             Rest of Europe

Latin America

•             Mexico
•             Brazil

Middle East & Africa

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Revenue of Antibody-oligonucleotide Conjugates (AOCs) in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Antibody-oligonucleotide Conjugates (AOCs) companies鈥 competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.

Chapter 7: Europe by Type, by Application and by country, revenue for each segment.

Chapter 8: China by Type, and by Application, revenue for each segment.

Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.

Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.

Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Antibody-oligonucleotide Conjugates (AOCs) revenue, gross margin, and recent development, etc.

Chapter 12: Analysis of industrial chain, sales channel, key raw materials and customers.

Chapter 13: Analyst’s Viewpoints/Conclusions

Table of Contents

1 Report Overview          1

1.1 Study Scope 1

1.2 Market Analysis by Type       1

1.2.1 Global Antibody-oligonucleotide Conjugates (AOCs) Market Size Growth Rate by Type: 2026 VS 2031            1

1.2.2 Site-specific Conjugation    3

1.2.3 Random Conjugation           4

1.3 Market by Application            5

1.3.1 Global Antibody-oligonucleotide Conjugates (AOCs) Market Share by Application: 2026 VS 2031        5

1.3.2 Rare and Genetic Diseases  7

1.3.3 Cancer Treatment  7

1.3.4 Central Nervous System Disorders   8

1.4 Assumptions and Limitations  8

1.5 Study Objectives       9

1.6 Years Considered      10

2 Global Growth Trends  11

2.1 Global Antibody-oligonucleotide Conjugates (AOCs) Market Perspective (2020-2031)            11

2.2 Global Antibody-oligonucleotide Conjugates (AOCs) Growth Trends by Region           12

2.2.1 Global Antibody-oligonucleotide Conjugates (AOCs) Market Size by Region: 2026 VS 2031     13

2.2.2 Antibody-oligonucleotide Conjugates (AOCs) Historic Market Size by Region (2020-2025)        14

2.2.3 Antibody-oligonucleotide Conjugates (AOCs) Forecasted Market Size by Region (2026-2031)         15

2.3 Antibody-oligonucleotide Conjugates (AOCs) Market Dynamics            16

2.3.1 Antibody-oligonucleotide Conjugates (AOCs) Industry Trends            16

2.3.2 Antibody-oligonucleotide Conjugates (AOCs) Market Drivers            18

2.3.3 Antibody-oligonucleotide Conjugates (AOCs) Market Challenges         19

2.3.4 Antibody-oligonucleotide Conjugates (AOCs) Market Restraints          19

3 Competition Landscape by Key Players 20

3.1 Global Revenue Antibody-oligonucleotide Conjugates (AOCs) by Players  20

3.1.1 Global Antibody-oligonucleotide Conjugates (AOCs) Revenue by Players (2020-2025)  20

3.1.2 Global Antibody-oligonucleotide Conjugates (AOCs) Revenue Market Share by Players (2020-2025)      21

3.2 Global Key Players of Antibody-oligonucleotide Conjugates (AOCs) Head office and Area Served        21

3.3 Global Key Players of Antibody-oligonucleotide Conjugates (AOCs), Product and Application  22

3.4 Global Key Players of Antibody-oligonucleotide Conjugates (AOCs), Date of Enter into This Industry  22

3.5 Mergers & Acquisitions, Expansion Plans        23

4 Antibody-oligonucleotide Conjugates (AOCs) Breakdown Data by Type     24

4.1 Global Antibody-oligonucleotide Conjugates (AOCs) Historic Market Size by Type (2020-2025)           24

4.2 Global Antibody-oligonucleotide Conjugates (AOCs) Forecasted Market Size by Type (2026-2031)           25

5 Antibody-oligonucleotide Conjugates (AOCs) Breakdown Data by Application         26

5.1 Global Antibody-oligonucleotide Conjugates (AOCs) Historic Market Size by Application (2020-2025)   26

5.2 Global Antibody-oligonucleotide Conjugates (AOCs) Forecasted Market Size by Application (2026-2031)   27

6 North America 28

6.1 North America Antibody-oligonucleotide Conjugates (AOCs) Market Size (2020-2031)            28

6.2 North America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type       28

6.2.1 North America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type (2020-2025)           28

6.2.2 North America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type (2026-2031)           29

6.2.3 North America Antibody-oligonucleotide Conjugates (AOCs) Market Share by Type (2026-2031)         30

6.3 North America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application          30

6.3.1 North America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2020-2025)   30

6.3.2 North America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2026-2031)   31

6.3.3 North America Antibody-oligonucleotide Conjugates (AOCs) Market Share by Application (2026-2031)            32

6.4 North America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country   32

6.4.1 North America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country: 2026 VS 2031    32

6.4.2 North America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country (2020-2025)       33

6.4.3 North America Antibody-oligonucleotide Conjugates (AOCs) Market Share by Country (2026-2031)     33

6.4.4 United States         34

6.4.5 Canada      35

7 Europe            36

7.1 Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size (2020-2031)           36

7.2 Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type      36

7.2.1 Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type (2020-2025)          36

7.2.2 Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type (2026-2031)          37

7.2.3 Europe Antibody-oligonucleotide Conjugates (AOCs) Market Share by Type (2026-2031)        38

7.3 Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application         38

7.3.1 Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2020-2025)  38

7.3.2 Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2026-2031)  39

7.3.3 Europe Antibody-oligonucleotide Conjugates (AOCs) Market Share by Application (2026-2031)           40

7.4 Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country  40

7.4.1 Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country: 2026 VS 2031   40

7.4.2 Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country (2020-2025)      41

7.4.3 Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country (2026-2031)      41

7.4.4 Germany    43

7.4.5 France       43

7.4.6 U.K.          44

7.4.7 Italy          45

7.4.8 Russia       45

8 China  46

8.1 China Antibody-oligonucleotide Conjugates (AOCs) Market Size (2020-2031)      46

8.2 China Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type 46

8.2.1 China Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type (2020-2025)          46

8.2.2 China Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type (2026-2031)          47

8.2.3 China Antibody-oligonucleotide Conjugates (AOCs) Market Share by Type (2027-2031)        47

8.3 China Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application    48

8.3.1 China Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2020-2025)  48

8.3.2 China Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2026-2031)  48

8.3.3 China Antibody-oligonucleotide Conjugates (AOCs) Market Share by Application (2027-2031)           49

9 Asia (excluding China)  50

9.1 Asia Antibody-oligonucleotide Conjugates (AOCs) Market Size (2020-2031)      50

9.2 Asia Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type 50

9.2.1 Asia Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type (2020-2025)     50

9.2.2 Asia Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type (2026-2031)     51

9.2.3 Asia Antibody-oligonucleotide Conjugates (AOCs) Market Share by Type (2020-2031)        52

9.3 Asia Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application    52

9.3.1 Asia Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2020-2025)         52

9.3.2 Asia Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2026-2031)         53

9.3.3 Asia Antibody-oligonucleotide Conjugates (AOCs) Market Share by Application (2027-2031)           54

9.4 Asia Antibody-oligonucleotide Conjugates (AOCs) Market Size by Region          54

9.4.1 Asia Antibody-oligonucleotide Conjugates (AOCs) Market Size by Region: 2027 VS 2031            54

9.4.2 Asia Antibody-oligonucleotide Conjugates (AOCs) Market Size by Region (2020-2025)   55

9.4.3 Asia Antibody-oligonucleotide Conjugates (AOCs) Market Size by Region (2026-2031)   55

9.4.4 Japan         57

9.4.5 South Korea           57

9.4.6 Southeast Asia       58

9.4.7 India          58

9.4.8 Australia    59

10 Middle East, Africa, and Latin America             60

10.1 Middle East, Africa, and Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Size (2020-2031)            60

10.2 Middle East, Africa, and Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type    61

10.2.1 Middle East, Africa, and Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type (2020-2025)    61

10.2.2 Middle East, Africa, and Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type (2026-2031)    61

10.2.3 Middle East, Africa, and Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Share by Type (2020-2031)    62

10.3 Middle East, Africa, and Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application            62

10.3.1 Middle East, Africa, and Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2020-2025)      62

10.3.2 Middle East, Africa, and Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2026-2031)      63

10.3.3 Middle East, Africa, and Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Share by Application (2020-2031)      63

10.4 Middle East, Africa, and Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country            64

10.4.1 Middle East, Africa, and Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country: 2026 VS 2031            64

10.4.2 Middle East, Africa, and Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country (2020-2025)    64

10.4.3 Middle East, Africa, and Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country (2026-2031)    65

10.4.4 Mexico    66

10.4.5 Brazil       66

10.4.6 Middle East & Africa         67

11 Key Players Profiles  68

11.1 Avidity Biosciences 68

11.1.1 Avidity Biosciences Company Details         68

11.1.2 Avidity Biosciences Business Overview      68

11.1.3 Avidity Biosciences Antibody-oligonucleotide Conjugates (AOCs) Introduction        69

11.1.4 Avidity Biosciences Revenue in Antibody-oligonucleotide Conjugates (AOCs) Business 2026 VS 2031          71

11.1.5 Avidity Biosciences Recent Development    72

11.2 Dyne Therapeutics  72

11.2.1 Dyne Therapeutics Company Details          72

11.2.2 Dyne Therapeutics Business Overview       73

11.2.3 Dyne Therapeutics Antibody-oligonucleotide Conjugates (AOCs) Introduction        73

11.2.4 Dyne Therapeutics Revenue in Antibody-oligonucleotide Conjugates (AOCs) Business in 2031        75

11.2.5 Dyne Therapeutics Recent Development     75

11.3 Tallac Therapeutics             76

11.3.1 Tallac Therapeutics Company Details         76

11.3.2 Tallac Therapeutics Business Overview     77

11.3.3 Tallac Therapeutics Antibody-oligonucleotide Conjugates (AOCs) Introduction        77

11.3.4 Tallac Therapeutics Revenue in Antibody-oligonucleotide Conjugates (AOCs) Business in 2031        78

11.3.5 Tallac Therapeutics Recent Development   78

11.4 Denali Therapeutics             79

11.4.1 Denali Therapeutics Company Details         79

11.4.2 Denali Therapeutics Business Overview     80

11.4.3 Denali Therapeutics Antibody-oligonucleotide Conjugates (AOCs) Introduction        80

11.4.4 Denali Therapeutics Revenue in Antibody-oligonucleotide Conjugates (AOCs) Business in 2031        81

11.4.5 Denali Therapeutics Recent Development   81

11.5 Gennao Bio 82

11.5.1 Gennao Bio Company Details         82

11.5.2 Gennao Bio Business Overview      83

11.5.3 Gennao Bio Antibody-oligonucleotide Conjugates (AOCs) Introduction       83

11.5.4 Gennao Bio Revenue in Antibody-oligonucleotide Conjugates (AOCs) Business in 2031 84

11.6 ChainGen Bio          84

11.6.1 ChainGen Bio Company Details      84

11.6.2 ChainGen Bio Business Overview   85

11.6.3 ChainGen Bio Antibody-oligonucleotide Conjugates (AOCs) Introduction       86

11.6.4 ChainGen Bio Revenue in Antibody-oligonucleotide Conjugates (AOCs) Business in 2031        86

12 Industry Chain and Sales Channels Analysis     87

12.1 Antibody-oligonucleotide Conjugates (AOCs) Industry Chain Analysis             87

12.2 Antibody-oligonucleotide Conjugates (AOCs) Key Raw Materials           87

12.2.1 Key Raw Materials            87

12.2.2 Raw Materials Key Suppliers         88

12.3 Antibody-oligonucleotide Conjugates (AOCs) Sales and Marketing          88

12.4 Antibody-oligonucleotide Conjugates (AOCs) Customers            89

13 Analyst’s Viewpoints/Conclusions        90

14 Appendix       91

14.1 Research Methodology         91

14.1.1 Methodology/Research Approach   91

14.1.2 Data Source         94

14.2 Author Details         97

14.3 Disclaimer  97

Tables and Figures

Table 1. Global Antibody-oligonucleotide Conjugates (AOCs) Market Size Growth Rate by Type (US$ Million): 2026 VS 2031            2

Table 2. Global Antibody-oligonucleotide Conjugates (AOCs) Market Size Growth by Application (US$ Million): 2026 VS 2031            5

Table 3. Global Antibody-oligonucleotide Conjugates (AOCs) Market Size Growth Rate (CAGR) by Region (US$ Million): 2026 VS 2031      13

Table 4. Global Antibody-oligonucleotide Conjugates (AOCs) Market Size by Region (2020-2025) & (US$ Million)          14

Table 5. Global Antibody-oligonucleotide Conjugates (AOCs) Market Share by Region (2020-2025)       15

Table 6. Global Antibody-oligonucleotide Conjugates (AOCs) Forecasted Market Size by Region (2026-2031) & (US$ Million)            15

Table 7. Global Antibody-oligonucleotide Conjugates (AOCs) Market Share by Region (2026-2031)       15

Table 8. Antibody-oligonucleotide Conjugates (AOCs) Market Trends  16

Table 9. Antibody-oligonucleotide Conjugates (AOCs) Market Drivers  18

Table 10. Antibody-oligonucleotide Conjugates (AOCs) Market Challenges         19

Table 11. Antibody-oligonucleotide Conjugates (AOCs) Market Restraints          19

Table 12. Global Antibody-oligonucleotide Conjugates (AOCs) Revenue by Players (2020-2025) & (US$ Million) 20

Table 13. Global Antibody-oligonucleotide Conjugates (AOCs) Market Share by Players (2020-2025)      21

Table 14. Global Key Players of Antibody-oligonucleotide Conjugates (AOCs), Headquarters and Area Served           21

Table 15. Global Key Players of Antibody-oligonucleotide Conjugates (AOCs), Product and Application         22

Table 16. Global Key Players of Antibody-oligonucleotide Conjugates (AOCs), Date of Enter into This Industry          23

Table 17. Mergers & Acquisitions, Expansion Plans           23

Table 18. Global Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type (2020-2025) & (US$ Million)            24

Table 19. Global Antibody-oligonucleotide Conjugates (AOCs) Revenue Market Share by Type (2020-205)         24

Table 20. Global Antibody-oligonucleotide Conjugates (AOCs) Forecasted Market Size by Type (2026-2031) & (US$ Million)            25

Table 21. Global Antibody-oligonucleotide Conjugates (AOCs) Revenue Market Share by Type (2026-2031)        25

Table 22. Global Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2020-2025) & (US$ Million)   26

Table 23. Global Antibody-oligonucleotide Conjugates (AOCs) Revenue Market Share by Application (2020-205) 26

Table 24. Global Antibody-oligonucleotide Conjugates (AOCs) Forecasted Market Size by Application (2026-2031) & (US$ Million)            27

Table 25. Global Antibody-oligonucleotide Conjugates (AOCs) Revenue Market Share by Application (2026-2031)           27

Table 26. North America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type (2020-2025) & (US$ Million)            28

Table 27. North America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type (2026-2031) & (US$ Million)            29

Table 28. North America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2020-2025) & (US$ Million)            30

Table 29. North America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2026-2031) & (US$ Million)            31

Table 30. North America Antibody-oligonucleotide Conjugates (AOCs) Growth Rate (CAGR) by Country (US$ Million): 2026 VS 2031      32

Table 31. North America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country (2020-2025) & (US$ Million)            33

Table 32. North America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country (2026-2031) & (US$ Million)            33

Table 33. Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type (2020-2025) & (US$ Million)            36

Table 34. Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type (2026-2031) & (US$ Million)            37

Table 35. Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2020-2025) & (US$ Million)   38

Table 36. Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2026-2031) & (US$ Million)   39

Table 37. Europe Antibody-oligonucleotide Conjugates (AOCs) Growth Rate (CAGR) by Country (US$ Million): 2026 VS 2031            40

Table 38. Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country (2020-2025) & (US$ Million)        41

Table 39. Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country (2026-2031) & (US$ Million)        41

Table 40. China Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type (2020-2025) & (US$ Million)            46

Table 41. China Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type (2026-2031) & (US$ Million)            47

Table 42. China Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2020-2025) & (US$ Million)   48

Table 43. China Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2026-2031) & (US$ Million)   48

Table 44. Asia Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type (2020-2025) & (US$ Million)           50

Table 45. Asia Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type (2026-2031) & (US$ Million)           51

Table 46. Asia Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2020-2025) & (US$ Million)  52

Table 47. Asia Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2026-2031) & (US$ Million)  53

Table 48. Asia Antibody-oligonucleotide Conjugates (AOCs) Growth Rate (CAGR) by Region (US$ Million): 2027 VS 2031         54

Table 49. Asia Antibody-oligonucleotide Conjugates (AOCs) Market Size by Region (2020-2025) & (US$ Million)         55

Table 50. Asia Antibody-oligonucleotide Conjugates (AOCs) Market Size by Region (2026-2031) & (US$ Million)         55

Table 51. Middle East, Africa, and Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type (2020-2025) & (US$ Million)     61

Table 52. Middle East, Africa, and Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type (2026-2031) & (US$ Million)     61

Table 53. Middle East, Africa, and Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2020-2025) & (US$ Million)       62

Table 54. Middle East, Africa, and Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2026-2031) & (US$ Million)       63

Table 55. Middle East, Africa, and Latin America Antibody-oligonucleotide Conjugates (AOCs) Growth Rate (CAGR) by Country (US$ Million): 2027 VS 2031        64

Table 56. Middle East, Africa, and Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country (2020-2025) & (US$ Million)     64

Table 57. Middle East, Africa, and Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country (2026-2031) & (US$ Million)     65

Table 58. Avidity Biosciences Company Details    68

Table 59. Avidity Biosciences Business Overview 68

Table 60. Avidity Biosciences Antibody-oligonucleotide Conjugates (AOCs) Product  69

Table 61. Avidity Biosciences Revenue in Antibody-oligonucleotide Conjugates (AOCs) Business 2026 VS 2031 & (US$ Million)            71

Table 62. Avidity Biosciences Recent Development           72

Table 63. Dyne Therapeutics Company Details      72

Table 64. Dyne Therapeutics Business Overview  73

Table 65. Dyne Therapeutics Antibody-oligonucleotide Conjugates (AOCs) Product  73

Table 66. Dyne Therapeutics Revenue in Antibody-oligonucleotide Conjugates (AOCs) Business in 2031 & (US$ Million)         75

Table 67. Dyne Therapeutics Recent Development            75

Table 68. Tallac Therapeutics Company Details    76

Table 69. Tallac Therapeutics Business Overview             77

Table 70. Tallac Therapeutics Antibody-oligonucleotide Conjugates (AOCs) Product  77

Table 71. Tallac Therapeutics Revenue in Antibody-oligonucleotide Conjugates (AOCs) Business in 2031 & (US$ Million)         78

Table 72. Tallac Therapeutics Recent Development           78

Table 73. Denali Therapeutics Company Details    79

Table 74. Denali Therapeutics Business Overview             80

Table 75. Denali Therapeutics Antibody-oligonucleotide Conjugates (AOCs) Product  80

Table 76. Denali Therapeutics Revenue in Antibody-oligonucleotide Conjugates (AOCs) Business in 2031 & (US$ Million)         81

Table 77. Denali Therapeutics Recent Development          81

Table 78. Gennao Bio Company Details    82

Table 79. Gennao Bio Business Overview 83

Table 80. Gennao Bio Antibody-oligonucleotide Conjugates (AOCs) Product  83

Table 81. Gennao Bio Revenue in Antibody-oligonucleotide Conjugates (AOCs) Business in 2031 & (US$ Million)         84

Table 82. ChainGen Bio Company Details 84

Table 83. ChainGen Bio Business Overview          85

Table 84. ChainGen Bio Antibody-oligonucleotide Conjugates (AOCs) Product  86

Table 85. ChainGen Bio Revenue in Antibody-oligonucleotide Conjugates (AOCs) Business in 2031 & (US$ Million)         86

Table 86. Raw Materials Key Suppliers Lists         88

Table 87. Antibody-oligonucleotide Conjugates (AOCs) Customers List       89

Table 88. Research Programs/Design for This Report        91

Table 89. Key Data Information from Secondary Sources   95

Table 90. Key Data Information from Primary Sources       96

List of Figures

Figure 1. Antibody-oligonucleotide Conjugates (AOCs) Picture            1

Figure 2. Global Antibody-oligonucleotide Conjugates (AOCs) Market Size Growth Rate by Type, (2020-2031) & (US$ Million)            2

Figure 3. Global Antibody-oligonucleotide Conjugates (AOCs) Market Share by Type: 2026 VS 2031      3

Figure 4. Site-specific Conjugation Picture           4

Figure 5. Random Conjugation Picture      5

Figure 6. Global Antibody-oligonucleotide Conjugates (AOCs) Market Size Growth Rate by Application, 2026-2031 (US$ Million)            6

Figure 7. Global Antibody-oligonucleotide Conjugates (AOCs) Market Share by Application: 2026 VS 2031         7

Figure 8. Antibody-oligonucleotide Conjugates (AOCs) Report Years Considered           10

Figure 9. Global Antibody-oligonucleotide Conjugates (AOCs) Market Size (US$ Million), Year-over-Year: 2020-2031    11

Figure 10. Global Antibody-oligonucleotide Conjugates (AOCs) Market Size, (US$ Million), 2026 VS 2031             12

Figure 11. Global Antibody-oligonucleotide Conjugates (AOCs) Market Share by Region: 2026 VS 2031    14

Figure 12. North America Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)            28

Figure 13. North America Antibody-oligonucleotide Conjugates (AOCs) Market Share by Type (2026-2031)          30

Figure 14. North America Antibody-oligonucleotide Conjugates (AOCs) Market Share by Application (2026-2031) 32

Figure 15. North America Antibody-oligonucleotide Conjugates (AOCs) Market Share by Country (2026-2031)      34

Figure 16. United States Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)            34

Figure 17. Canada Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)       35

Figure 18. Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)       36

Figure 19. Europe Antibody-oligonucleotide Conjugates (AOCs) Market Share by Type (2026-2031)         38

Figure 20. Europe Antibody-oligonucleotide Conjugates (AOCs) Market Share by Application (2026-2031)            40

Figure 21. Europe Antibody-oligonucleotide Conjugates (AOCs) Market Share by Country (2026-2031)     42

Figure 22. Germany Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)       43

Figure 23. France Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)       43

Figure 24. U.K. Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)       44

Figure 25. Italy Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)       45

Figure 26. Russia Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)       45

Figure 27. China Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)       46

Figure 28. China Antibody-oligonucleotide Conjugates (AOCs) Market Share by Type (2027-2031)         47

Figure 29. China Antibody-oligonucleotide Conjugates (AOCs) Market Share by Application (2027-2031)            49

Figure 30. Asia Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)       50

Figure 31. Asia Antibody-oligonucleotide Conjugates (AOCs) Market Share by Type (2020-2031)         52

Figure 32. Asia Antibody-oligonucleotide Conjugates (AOCs) Market Share by Application (2027-2031)            54

Figure 33. Asia Antibody-oligonucleotide Conjugates (AOCs) Market Share by Region (2020-2031)       56

Figure 34. Japan Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)       57

Figure 35. South Korea Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)       57

Figure 36. Southeast Asia Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)            58

Figure 37. India Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)       58

Figure 38. Australia Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)       59

Figure 39. Middle East, Africa, and Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)     60

Figure 40. Middle East, Africa, and Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Share by Type (2020-2031)    62

Figure 41. Middle East, Africa, and Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Share by Application (2020-2031)      63

Figure 42. Middle East, Africa, and Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Share by Country (2027-2031)    65

Figure 43. Mexico Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)       66

Figure 44. Brazil Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)       66

Figure 45. Middle East & Africa Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)      67

Figure 46. Antibody-oligonucleotide Conjugates (AOCs) Value Chain     87

Figure 47. Bottom-up and Top-down Approaches for This Report            93

Figure 48. Data Triangulation      94

Figure 49. Key Executives Interviewed    96

QYResearchは広範な市場を対象にし、多様な市場調査レポートを出版している中国北京に本社をおく市場調査会社です。QYResearch出版の市場調査レポートに関するご質問やサンプルページのご依頼等はいつでもお気軽にお問合せください。

QYResearch 出版レポート一覧

ご購入に関するご案内

価格・納期について

• 価格
  • ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。手数料（ハンドリングチャージ）無料。
• ライセンス
  • シングルユーザライセンス
    • 1名のみレポートファイル閲覧可のライセンスです。
    • 提供ファイルはPDFファイルです。
    • 納品ファイルは印刷可、コピー＆ペースト可。
  • マルチユーザライセンス
    • 同一企業内20名までレポートファイルの閲覧可のライセンスです。
    • 提供ファイルはPDFとExcelファイルです。
    • 納品ファイルは印刷可、コピー＆ペースト可。
  • エンタープライズライセンス
    • 同一企業および関連会社内において人数無制限でレポートファイルの閲覧可のライセンスです。
    • 提供ファイルはPDFとExcelファイルです。
    • 納品ファイルは印刷可、コピー＆ペースト可。
• 納期
  • 既刊レポート：ご注文後3営業日以内
  • オンデマンドレポート：通常7営業日前後

• 納品形態
  • Eメール

注文方法

• レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでのご注文をお待ちしております。

その他

• 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。